The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Inclusion Criteria: * Patients diagnosed with ovarian cancer (any histological type) and possessing complete pathological hematoxylin and eosin (HE) stained slides and paraffin-embedded tissue blocks. * Patients must be 18 years of age or older. * Patients should not have concurrent multiple primary cancers. * Patients must undergo an MRI or CT scan prior to starting treatment. * According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria, patients must have at least one measurable lesion. * Participants must provide informed consent, voluntarily cooperate with clinical follow-up, and sign an informed consent form. Exclusion Criteria: * Patients who do not have accessible tumor tissue required for Homologous Recombination Deficiency (HRD) testing. * Patients whose clinical records are incomplete, making it impossible to effectively compare treatment efficacy. * Patients who are lost to follow-up and for whom subsequent treatment outcomes cannot be tracked.